OANDA Prop Trader enables crypto payments, giving customers the option to pay for Challenges using cryptocurrencies, and launches $10,000 Giveaway Sweepstakes
OANDA announced today that it has introduced cryptocurrencies* as a payment method in its prop trading business, OANDA Prop Trader, giving customers globally the option to pay for trading Challenges using cryptocurrencies via the program’s user portal.
OANDA Prop Trader is a program that enables self-directed traders to become signal providers, on a profit-sharing basis, to the firm’s proprietary trading business. To qualify for the program, participants need to purchase and complete a Challenge. Through the Challenge, potential signal providers demonstrate their ability to generate profits and manage risk. With a variety of payment methods, participants can now purchase a Challenge with cryptocurrencies* and start assessing their trading skills immediately.
Lucian Lauerman, Head of Digital Assets and Deputy COO at OANDA, commented, “We’re pleased to announce that we’re adding crypto as a payment method in response to rising global demand. A large number of “tech-driven consumers” in the countries serviced by OANDA Prop Trader are embracing cryptocurrencies, so this is opening new doors for those traders who want to maximise the digital economy as a gateway into prop trading.”
$10,000 Giveaway Sweepstakes Opens More Possibilities For Aspiring Prop Traders
But that’s not all. OANDA Prop Trader is also launching an exciting $10,000 Giveaway Sweepstakes, open to aspiring traders residing in all the countries where OANDA Prop Trader is made available.
Entrants can participate in the Sweepstakes by registering for an OANDA Prop Trader account to get a chance to win a $100 voucher to purchase a Challenge. Each registration earns one entry into the drawing, and one hundred winners will be randomly selected to share a total prize pool of $10,000.
“At OANDA Prop Trader, we value our customers and are committed to rewarding their journey toward becoming successful traders. The $10,000 Giveaway Sweepstakes represents a fun and affordable route for many aspiring traders to get a chance to test their skills in a prop trading environment,” said Crystal Lok, Head of Emerging Markets at OANDA.
*Payments are accepted in both stablecoins and popular cryptos: BTC , AAVE , ADA, BCH , BNB, , BSV, DOGE, DOT, ETH, LINK, LTC, MATIC, NANO, QTUM, SHIB, SOL, TRX, TUSD, USDC, USDT20, USDTTRC20.
About OANDA
Founded in 1996, OANDA is one of the world’s leading online trading groups, offering multi-asset trading, currency data, and analytics to retail and corporate clients around the globe.
From its roots providing free exchange rate data on the internet to launching a forex trading platform that helped pioneer web-based currency trading, OANDA remains dedicated to building smarter trading experiences.
With regulated entities in many of the world’s most active financial markets, including New York, Toronto, London, Warsaw, Singapore, Tokyo and Sydney, OANDA enables retail clients to trade in a variety of asset classes on an award-winning trading platform. Depending on geographical location, these may include derivatives of global market indices, equities, commodities, treasuries, precious metals, forex, and cryptocurrencies.
https://www.prnewswire.com/news-releases/oanda-prop-trader-enables-crypto-payments-and-launches-10-000-giveaway-sweepstakes-302197671.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
